Figure 1From: Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockadeChange in T-score in the ZA-treated and control groups. (a) T-score at baseline and 12 months in each group; (b) Mean ± SE change in T-score from baseline in the two groups. SE, standard error of the mean; ZA, zoledronic acid; Ctrl, control.Back to article page